Condition: Parkinson's Disease (PD) · Mild to Moderate Parkinson's Disease · Early Stage Parkinson's Disease · Sponsor: Mission Therapeutics
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
This description comes directly from the study's public registry record.
Sarah J Fritchley, PhD · sfritchley@missiontherapeutics.com
Always discuss trial participation with your own doctor first.
| The Royal Adelaide Hospital | Adelaide, Australia | Not Yet Recruiting |
| Doherty Clinical Trials | Melbourne, Australia | Not Yet Recruiting |
| Monash Health, Kingston Centre | Melbourne, Australia | Not Yet Recruiting |
| Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon | Lille, France | Recruiting |
| Hôpital Henri-Mondor (Créteil, AP-HP), Paris | Paris, France | Not Yet Recruiting |
| Pitie-Salpetriere Hospital, Paris | Paris, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse | Toulouse, France | Not Yet Recruiting |
| Technische Universitaet Dresden, Dresden | Dresden, Germany | Not Yet Recruiting |
| Cambridge Biomedical Research Centre, Cambridge | Cambridge, United Kingdom | Not Yet Recruiting |
| Neuroclnx, Glasgow | Glasgow, United Kingdom | Not Yet Recruiting |
| Royal Liverpool University Hospital | Liverpool, United Kingdom | Recruiting |
| Parexel | London, United Kingdom | Completed |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07630545